Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 10;89(15):1569-1577.
doi: 10.1212/WNL.0000000000004490. Epub 2017 Sep 6.

Nonlinear temporal dynamics of cerebral small vessel disease: The RUN DMC study

Affiliations

Nonlinear temporal dynamics of cerebral small vessel disease: The RUN DMC study

Esther M C van Leijsen et al. Neurology. .

Abstract

Objective: To investigate the temporal dynamics of cerebral small vessel disease (SVD) by 3 consecutive assessments over a period of 9 years, distinguishing progression from regression.

Methods: Changes in SVD markers of 276 participants of the Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Imaging Cohort (RUN DMC) cohort were assessed at 3 time points over 9 years. We assessed white matter hyperintensities (WMH) volume by semiautomatic segmentation and rated lacunes and microbleeds manually. We categorized baseline WMH severity as mild, moderate, or severe according to the modified Fazekas scale. We performed mixed-effects regression analysis including a quadratic term for increasing age.

Results: Mean WMH progression over 9 years was 4.7 mL (0.54 mL/y; interquartile range 0.95-5.5 mL), 20.3% of patients had incident lacunes (2.3%/y), and 18.9% had incident microbleeds (2.2%/y). WMH volume declined in 9.4% of the participants during the first follow-up interval, but only for 1 participant (0.4%) throughout the whole follow-up. Lacunes disappeared in 3.6% and microbleeds in 5.7% of the participants. WMH progression accelerated over time: including a quadratic term for increasing age during follow-up significantly improved the model (p < 0.001). SVD progression was predominantly seen in participants with moderate to severe WMH at baseline compared to those with mild WMH (odds ratio [OR] 35.5, 95% confidence interval [CI] 15.8-80.0, p < 0.001 for WMH progression; OR 5.7, 95% CI 2.8-11.2, p < 0.001 for incident lacunes; and OR 2.9, 95% CI 1.4-5.9, p = 0.003 for incident microbleeds).

Conclusions: SVD progression is nonlinear, accelerating over time, and a highly dynamic process, with progression interrupted by reduction in some, in a population that on average shows progression.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Temporal dynamics of white matter hyperintensities (WMH) progression
(A) Change in WMH volume (mL) over 3 time points by age at individual level. (B) Acceleration of WMH volume change over 2 follow-up periods (mL/y) by age at individual level. (C) Change in WMH volume (mL) over 3 time points by age at individual level stratified by baseline WMH severity. Baseline WMH severity was classified as mild (Fazekas 0–1; n = 211), moderate (Fazekas 2; n = 33), or severe (Fazekas 3; n = 20). Smoothed curves using loess smoothing express average WMH change with increasing age.
Figure 2
Figure 2. Lacunes and microbleeds no longer visible on follow-up imaging
Examples of a lacune that is no longer detectable on follow-up imaging (A), which appears to be assimilated by the ventricle. Microbleeds (B) appear to have faded away over time.
Figure 3
Figure 3. White matter hyperintensities (WMH) probability maps stratified by baseline WMH severity
Probabilities of presence of WMH stratified by baseline WMH severity, color-coded in percentage from 5% to 75%. Baseline WMH severity is determined as mild (Fazekas 0–1; n = 211), moderate (Fazekas 2; n = 33), or severe (Fazekas 3; n = 20). The overall 9-year change is shown in the right column. Probability maps through the whole brain can be seen in video 4.

References

    1. Wardlaw JM, Smith EE, Biessels GJ, et al. . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822–838. - PMC - PubMed
    1. Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol 2015;11:157–165. - PubMed
    1. Banerjee G, Wilson D, Jager HR, Werring DJ. Novel imaging techniques in cerebral small vessel diseases and vascular cognitive impairment. Biochim Biophys Acta 2016;1862:926–938. - PubMed
    1. Benjamin P, Zeestraten E, Lambert C, et al. . Progression of MRI markers in cerebral small vessel disease: sample size considerations for clinical trials. J Cereb Blood Flow Metab 2016;36:228–240. - PMC - PubMed
    1. Gouw AA, van der Flier WM, van Straaten EC, et al. . Reliability and sensitivity of visual scales versus volumetry for evaluating white matter hyperintensity progression. Cerebrovasc Dis 2008;25:247–253. - PubMed

LinkOut - more resources